Loading…
STAT3 and STAT5B Mutations in T/NK-Cell Chronic Lymphoproliferative Disorders of Large Granular Lymphocytes (LGL): Association with Disease Features
and ( ) mutations are the most common mutations in T-cell large granular lymphocytic leukemia (T-LGLL) and chronic lymphoproliferative disorders of NK cells (CLPD-NK), but their clinical impact remains unknown. We investigated the frequency and type of mutations in FACS-sorted populations of expande...
Saved in:
Published in: | Cancers 2020-11, Vol.12 (12), p.3508 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | and
(
) mutations are the most common mutations in T-cell large granular lymphocytic leukemia (T-LGLL) and chronic lymphoproliferative disorders of NK cells (CLPD-NK), but their clinical impact remains unknown. We investigated the frequency and type of
mutations in FACS-sorted populations of expanded T/NK-LGL from 100 (82 clonal; 6 oligoclonal; 12 polyclonal) patients, and its relationship with disease features. Seventeen non-LGL T-CLPD patients and 628 age-matched healthy donors were analyzed as controls.
(
= 30) and
(
= 1) mutations were detected in 28/82 clonal T/NK-LGLL patients (34%), while absent (0/18, 0%) among oligoclonal/polyclonal LGL-lymphocytosis. Mutations were found across all diagnostic subgroups: TCD8
-LGLL, 36%; CLPD-NK, 38%; TCD4
-LGLL, 7%; Tαβ
DP-LGLL, 100%; Tαβ
DN-LGLL, 50%; Tγδ
-LGLL, 44%.
-mutated T-LGLL/CLPD-NK showed overall reduced (
< 0.05) blood counts of most normal leukocyte subsets, with a higher rate (vs. nonmutated LGLL) of neutropenia (
= 0.04), severe neutropenia (
= 0.02), and cases requiring treatment (
= 0.0001), together with a shorter time-to-therapy (
= 0.0001), particularly in non-Y640F
mutated patients. These findings confirm and extend on previous observations about the high prevalence of
mutations across different subtypes of LGLL, and its association with a more marked decrease of all major blood-cell subsets and a shortened time-to-therapy. |
---|---|
ISSN: | 2072-6694 2072-6694 |
DOI: | 10.3390/cancers12123508 |